Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer

Cancer Letters

Volumn 335, Issue 1, 2013, Pages 41-51

  Yabuuchi, Shinichi ^a,c   Pai, Shweta G ^a   Campbell, Nathaniel R ^a   De Wilde, Roeland F ^a   De Oliveira, Elizabeth ^a   Korangath, Preethi ^a   Streppel, Mirte M ^a   Rasheed, Zeshaan A ^a   Hidalgo, Manuel ^b   Maitra, Anirban ^a   Rajeshkumar, N V ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gamma secretase inhibitor; Notch; Pancreatic cancer; PF 03084014

Indexed keywords

ALDH PROTEIN; CD22 ANTIGEN; CELL MARKER; GEMCITABINE; HERMES ANTIGEN; HEY 1 PROTEIN; NOTCH RECEPTOR; PF 3084014; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TETRAHYDRONAPHTHALENES; TUMOR BURDEN; TUMOR CELLS, CULTURED; VALINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878459227     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.01.054     Document Type: Article

References (50)

1. Feig C., Gopinathan A., Neesse A., Chan D.S., Cook N., Tuveson D.A. The pancreas cancer microenvironment. Clin. Cancer Res. 2012, 18:4266-4276.
2. Maitra A., Hruban R.H. Pancreatic cancer. Annu. Rev. Pathol. 2008, 3:157-188.
3. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 2010, 362:1605-1617.
4. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
5. De La O.J., Emerson L.L., Goodman J.L., Froebe S.C., Illum B.E., Curtis A.B., Murtaugh L.C. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:18907-18912.
6. Weijzen S., Rizzo P., Braid M., Vaishnav R., Jonkheer S.M., Zlobin A., Osborne B.A., Gottipati S., Aster J.C., Hahn W.C., Rudolf M., Siziopikou K., Kast W.M., Miele L. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat. Med. 2002, 8:979-986.
7. Van Cutsem E., van de Velde H., Karasek P., Oettle H., Vervenne W.L., Szawlowski A., Schoffski P., Post S., Verslype C., Neumann H., Safran H., Humblet Y., Perez Ruixo J., Ma Y., Von Hoff D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 2004, 22:1430-1438.
8. Garcia A., Kandel J.J. Notch: a key regulator of tumor angiogenesis and metastasis. Histol. Histopathol. 2012, 27:151-156.
9. Wang Z., Zhang Y., Li Y., Banerjee S., Liao J., Sarkar F.H. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther. 2006, 5:483-493.
10. Wang Z., Banerjee S., Li Y., Rahman K.M., Zhang Y., Sarkar F.H. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006, 66:2778-2784.
11. Cook N., Frese K.K., Bapiro T.E., Jacobetz M.A., Gopinathan A., Miller J.L., Rao S.S., Demuth T., Howat W.J., Jodrell D.I., Tuveson D.A. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J. Exp. Med. 2012, 209:437-444.
12. D'Souza B., Miyamoto A., Weinmaster G. The many facets of Notch ligands. Oncogene 2008, 27:5148-5167.
13. Dufraine J., Funahashi Y., Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008, 27:5132-5137.
14. Wei P., Walls M., Qiu M., Ding R., Denlinger R.H., Wong A., Tsaparikos K., Jani J.P., Hosea N., Sands M., Randolph S., Smeal T. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol. Cancer Ther. 2010, 9:1618-1628.
15. Lanz T.A., Wood K.M., Richter K.E., Nolan C.E., Becker S.L., Pozdnyakov N., Martin B.A., Du P., Oborski C.E., Wood D.E., Brown T.M., Finley J.E., Sokolowski S.A., Hicks C.D., Coffman K.J., Geoghegan K.F., Brodney M.A., Liston D., Tate B. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014. J. Pharmacol. Exp. Ther. 2010, 334:269-277.
16. Zhang C.C., Pavlicek A., Zhang Q., Lira M.E., Painter C.L., Yan Z., Zheng X., Lee N.V., Ozeck M., Qiu M., Zong Q., Lappin P.B., Wong A., Rejto P.A., Smeal T., Christensen J.G. Biomarker and pharmacologic evaluation of the gamma-secretase inhibitor PF-03084014 in breast cancer models. Clin. Cancer Res. 2012, 18:5008-5019.
17. Samon J.B., Castillo-Martin M., Hadler M., Ambesi-Impiobato A., Paietta E., Racevskis J., Wiernik P.H., Rowe J.M., Jakubczak J., Randolph S., Cordon-Cardo C., Ferrando A.A. Preclinical analysis of the gamma-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol. Cancer Ther. 2012, 11:1565-1575.
18. Mizuma M., Rasheed Z.A., Yabuuchi S., Omura N., Campbell N.R., de Wilde R.F., De Oliveira E., Zhang Q., Puig O., Matsui W., Hidalgo M., Maitra A., Rajeshkumar N.V. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol. Cancer Ther. 2012, 11:1999-2009.
19. Donadelli M., Dando I., Zaniboni T., Costanzo C., Dalla Pozza E., Scupoli M.T., Scarpa A., Zappavigna S., Marra M., Abbruzzese A., Bifulco M., Caraglia M., Palmieri M. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011, 2:e152.
20. Rasheed Z.A., Yang J., Wang Q., Kowalski J., Freed I., Murter C., Hong S.M., Koorstra J.B., Rajeshkumar N.V., He X., Goggins M., Iacobuzio-Donahue C., Berman D.M., Laheru D., Jimeno A., Hidalgo M., Maitra A., Matsui W. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J. Natl Cancer Inst. 2010, 102:340-351.
21. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
22. Ishizawa K., Rasheed Z.A., Karisch R., Wang Q., Kowalski J., Susky E., Pereira K., Karamboulas C., Moghal N., Rajeshkumar N.V., Hidalgo M., Tsao M., Ailles L., Waddell T.K., Maitra A., Neel B.G., Matsui W. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 2010, 7:279-282.
23. Rajeshkumar N.V., Rasheed Z.A., Garcia-Garcia E., Lopez-Rios F., Fujiwara K., Matsui W.H., Hidalgo M. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol. Cancer Ther. 2010, 9:2582-2592.
24. Rajeshkumar N.V., Tan A.C., De Oliveira E., Womack C., Wombwell H., Morgan S., Warren M.V., Walker J., Green T.P., Jimeno A., Messersmith W.A., Hidalgo M. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin. Cancer Res. 2009, 15:4138-4146.
25. Jiang J., Thyagarajan-Sahu A., Krchnak V., Jedinak A., Sandusky G.E., Sliva D. NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo. PLoS ONE 2012, 7:e34283.
26. Hanrahan A.J., Solit D.B. RAF/MEK dependence of KRAS-mutant pancreatic ductal adenocarcinomas. Cancer Discov. 2012, 2:666-669.
27. De La O.J., Murtaugh L.C. Notch and Kras in pancreatic cancer: at the crossroads of mutation, differentiation and signaling. Cell Cycle 2009, 8:1860-1864.
28. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
29. Al-Ejeh F., Smart C.E., Morrison B.J., Chenevix-Trench G., Lopez J.A., Lakhani S.R., Brown M.P., Khanna K.K. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 2011, 32:650-658.
30. Meng R.D., Shelton C.C., Li Y.M., Qin L.X., Notterman D., Paty P.B., Schwartz G.K. Gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res. 2009, 69:573-582.
31. Groth C., Fortini M.E. Therapeutic approaches to modulating Notch signaling: current challenges and future prospects. Semin. Cell Dev. Biol. 2012, 23:465-472.
32. Wang Z., Li Y., Ahmad A., Azmi A.S., Banerjee S., Kong D., Sarkar F.H. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim. Biophys. Acta 1806, 2010:258-267.
33. Plentz R., Park J.S., Rhim A.D., Abravanel D., Hezel A.F., Sharma S.V., Gurumurthy S., Deshpande V., Kenific C., Settleman J., Majumder P.K., Stanger B.Z., Bardeesy N. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 2009, 136:1741-1749. (e1746).
34. Wang Z., Ahmad A., Li Y., Azmi A.S., Miele L., Sarkar F.H. Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Res. 2011, 31:1105-1113.
35. Pannuti A., Foreman K., Rizzo P., Osipo C., Golde T., Osborne B., Miele L. Targeting Notch to target cancer stem cells. Clin. Cancer Res. 2010, 16:3141-3152.
36. Feldmann G., Mishra A., Bisht S., Karikari C., Garrido-Laguna I., Rasheed Z., Ottenhof N.A., Dadon T., Alvarez H., Fendrich V., Rajeshkumar N.V., Matsui W., Brossart P., Hidalgo M., Bannerji R., Maitra A., Nelkin B.D. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol. Ther. 2011, 12:598-609.
37. Garrido-Laguna I., Uson M., Rajeshkumar N.V., Tan A.C., de Oliveira E., Karikari C., Villaroel M.C., Salomon A., Taylor G., Sharma R., Hruban R.H., Maitra A., Laheru D., Rubio-Viqueira B., Jimeno A., Hidalgo M. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin. Cancer Res. 2011, 17:5793-5800.
38. Shah A.N., Summy J.M., Zhang J., Park S.I., Parikh N.U., Gallick G.E. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 2007, 14:3629-3637.
39. Wang Z., Li Y., Kong D., Banerjee S., Ahmad A., Azmi A.S., Ali S., Abbruzzese J.L., Gallick G.E., Sarkar F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69:2400-2407.
40. C. Zhang, Y. Yan, Q. Zong, D. Fang, C. Painter, Q. Zhang, A. Pavlicek, M. Lira, A. John-Baptiste, J. Christensen, Gamma-secretase inhibitor PF-03084014 diminishes the tumor-initiating cells and demonstrates synergy with docetaxel in breast cancer xenograft models, in: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research, 2012 March 31-April 4, Chicago, IL. Philadelphia (PA): Cancer Res 2012;72(8 Suppl):Abstract nr 3492 (2012).
41. Arcaroli J.J., Powell R.W., Varella-Garcia M., McManus M., Tan A.C., Quackenbush K.S., Pitts T.M., Gao D., Spreafico A., Dasari A., Touban B.M., Messersmith W.A. ALDH(+) tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a gamma-secretase inhibitor and irinotecan in colorectal cancer. Mol. Oncol. 2012, 6:370-381.
42. Krop I., Demuth T., Guthrie T., Wen P.Y., Mason W.P., Chinnaiyan P., Butowski N., Groves M.D., Kesari S., Freedman S.J., Blackman S., Watters J., Loboda A., Podtelezhnikov A., Lunceford J., Chen C., Giannotti M., Hing J., Beckman R., Lorusso P. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J. Clin. Oncol. 2012, 30:2307-2313.
43. W.A. Messersmith, P. Lorusso, J.M. Cleary, A. Dasari, X. Zhang, M.N. Shaik, R.D. Courtney, S. Randolph, G. Shapiro, A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors, J. Clin. Oncol. 29 (2011) (suppl; abstr 3100).
44. Rajeshkumar N.V., De Oliveira E., Ottenhof N., Watters J., Brooks D., Demuth T., Shumway S.D., Mizuarai S., Hirai H., Maitra A., Hidalgo M. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin. Cancer Res. 2011, 17:2799-2806.
45. Jones R.J., Matsui W.H., Smith B.D. Cancer stem cells: are we missing the target?. J. Natl Cancer Inst. 2004, 96:583-585.
46. Gupta P.B., Onder T.T., Jiang G., Tao K., Kuperwasser C., Weinberg R.A., Lander E.S. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
47. Purow B. Notch inhibition as a promising new approach to cancer therapy. Adv. Exp. Med. Biol. 2012, 727:305-319.
48. Garber K. Notch emerges as new cancer drug target. J. Natl. Cancer Inst. 2007, 99:1284-1285.
49. Real P.J., Tosello V., Palomero T., Castillo M., Hernando E., de Stanchina E., Sulis M.L., Barnes K., Sawai C., Homminga I., Meijerink J., Aifantis I., Basso G., Cordon-Cardo C., Ai W., Ferrando A. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat. Med. 2009, 15:50-58.
50. A.F. Schott, M. Landis, G. Dontu, K.A. Griffith, R.M. Layman, I. Krop, L.A. Paskett, H. Wong, L.E. Drobolecki, A.M. Froehlich, J. Paranilam, D.F. Hayes, M.S. Wicha, J.C. Chang, Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors, Clin. Cancer Res., in press. [Epub ahead of print].